Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions: A randomized study

A. Kessinger, Robert Swift Wigton

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Both bleomycin and tetracycline have been suggested as the sclerosing agent of choice in the management of malignant pleural effusions. To determine if one drug is superior to the other in this role, patients with malignant pleural effusions were randomly assigned to receive either bleomycin or tetracylcine in the previously evacuated pleural space through a thoracostomy tube. Following instillation of the assigned agent, the tube was clamped for 8 hours and then reattached to suction. When the chest tube drainage had slowed to less than 40 ml in a 24‐hour period or if 7 days had passed, the tube was removed. Pleural sclerosis was attempted 42 times in 34 patients. No statistically significant differences were found between the two treatment groups when prevention of effusion reaccumulation and time to removal of the chest tube (efficiency) were compared. Side effects including pleural pain and fever, occurred with both agents, but were manageable. Since one drug was not clearly superior to the other, and bleomycin is more costly, we suggest that tetracycline rather than bleomycin be used when pleural sclerosis is needed to manage malignant pleural effusions.

Original languageEnglish (US)
Pages (from-to)81-83
Number of pages3
JournalJournal of Surgical Oncology
Volume36
Issue number2
DOIs
StatePublished - Oct 1987

Fingerprint

Malignant Pleural Effusion
Bleomycin
Tetracycline
Chest Tubes
Sclerosis
Thoracostomy
Sclerosing Solutions
Suction
Pharmaceutical Preparations
Drainage
Fever
Pain
indium-bleomycin

Keywords

  • bleomycin
  • malignant pleural effusion
  • sclerosis
  • tetracyline

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions : A randomized study. / Kessinger, A.; Wigton, Robert Swift.

In: Journal of Surgical Oncology, Vol. 36, No. 2, 10.1987, p. 81-83.

Research output: Contribution to journalArticle

@article{b5c14dd7b1e84cedbc726fa72badda8b,
title = "Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions: A randomized study",
abstract = "Both bleomycin and tetracycline have been suggested as the sclerosing agent of choice in the management of malignant pleural effusions. To determine if one drug is superior to the other in this role, patients with malignant pleural effusions were randomly assigned to receive either bleomycin or tetracylcine in the previously evacuated pleural space through a thoracostomy tube. Following instillation of the assigned agent, the tube was clamped for 8 hours and then reattached to suction. When the chest tube drainage had slowed to less than 40 ml in a 24‐hour period or if 7 days had passed, the tube was removed. Pleural sclerosis was attempted 42 times in 34 patients. No statistically significant differences were found between the two treatment groups when prevention of effusion reaccumulation and time to removal of the chest tube (efficiency) were compared. Side effects including pleural pain and fever, occurred with both agents, but were manageable. Since one drug was not clearly superior to the other, and bleomycin is more costly, we suggest that tetracycline rather than bleomycin be used when pleural sclerosis is needed to manage malignant pleural effusions.",
keywords = "bleomycin, malignant pleural effusion, sclerosis, tetracyline",
author = "A. Kessinger and Wigton, {Robert Swift}",
year = "1987",
month = "10",
doi = "10.1002/jso.2930360202",
language = "English (US)",
volume = "36",
pages = "81--83",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions

T2 - A randomized study

AU - Kessinger, A.

AU - Wigton, Robert Swift

PY - 1987/10

Y1 - 1987/10

N2 - Both bleomycin and tetracycline have been suggested as the sclerosing agent of choice in the management of malignant pleural effusions. To determine if one drug is superior to the other in this role, patients with malignant pleural effusions were randomly assigned to receive either bleomycin or tetracylcine in the previously evacuated pleural space through a thoracostomy tube. Following instillation of the assigned agent, the tube was clamped for 8 hours and then reattached to suction. When the chest tube drainage had slowed to less than 40 ml in a 24‐hour period or if 7 days had passed, the tube was removed. Pleural sclerosis was attempted 42 times in 34 patients. No statistically significant differences were found between the two treatment groups when prevention of effusion reaccumulation and time to removal of the chest tube (efficiency) were compared. Side effects including pleural pain and fever, occurred with both agents, but were manageable. Since one drug was not clearly superior to the other, and bleomycin is more costly, we suggest that tetracycline rather than bleomycin be used when pleural sclerosis is needed to manage malignant pleural effusions.

AB - Both bleomycin and tetracycline have been suggested as the sclerosing agent of choice in the management of malignant pleural effusions. To determine if one drug is superior to the other in this role, patients with malignant pleural effusions were randomly assigned to receive either bleomycin or tetracylcine in the previously evacuated pleural space through a thoracostomy tube. Following instillation of the assigned agent, the tube was clamped for 8 hours and then reattached to suction. When the chest tube drainage had slowed to less than 40 ml in a 24‐hour period or if 7 days had passed, the tube was removed. Pleural sclerosis was attempted 42 times in 34 patients. No statistically significant differences were found between the two treatment groups when prevention of effusion reaccumulation and time to removal of the chest tube (efficiency) were compared. Side effects including pleural pain and fever, occurred with both agents, but were manageable. Since one drug was not clearly superior to the other, and bleomycin is more costly, we suggest that tetracycline rather than bleomycin be used when pleural sclerosis is needed to manage malignant pleural effusions.

KW - bleomycin

KW - malignant pleural effusion

KW - sclerosis

KW - tetracyline

UR - http://www.scopus.com/inward/record.url?scp=0023201550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023201550&partnerID=8YFLogxK

U2 - 10.1002/jso.2930360202

DO - 10.1002/jso.2930360202

M3 - Article

C2 - 2443762

AN - SCOPUS:0023201550

VL - 36

SP - 81

EP - 83

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -